Yüksel Ürün: Carboplatin plus docataxel for patients with biallelic HRR gene alterations in metastatic castration-resistant prostate cancer

Yüksel Ürün shared a post on X:

“The ABCD Trial shows promising results with carboplatin and docetaxel for patients with biallelic HRR gene alterations in metastatic castration-resistant prostate cancer:

• 69% achieved a PSA50 response.
• Median Progression-Free Survival (PFS): 8.4 months.
• Median Overall survival (OS): 1.42 years.
• Especially effective in BRCA1/2, PALB2 subgroup (PSA50 R: 78%).
• These findings suggest that carboplatin and docetaxel is a viable option, with further research ongoing.”

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.